H
Hideaki Ijichi
Researcher at University of Tokyo
Publications - 120
Citations - 4868
Hideaki Ijichi is an academic researcher from University of Tokyo. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 37, co-authored 108 publications receiving 4269 citations.
Papers
More filters
Journal ArticleDOI
Correction: Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion
Tsuneo Ikenoue,Yumi Terakado,Hayato Nakagawa,Yohko Hikiba,Tomoaki Fujii,Daisuke Matsubara,Rei Noguchi,Chi Zhu,Keisuke Yamamoto,Yotaro Kudo,Yoshinari Asaoka,Kiyoshi Yamaguchi,Hideaki Ijichi,Keisuke Tateishi,Noriyoshi Fukushima,Shin Maeda,Kazuhiko Koike,Yoichi Furukawa +17 more
TL;DR: Generation of the mice with liver-specific KrasG12D expression and Pten deletion and strategy to generate the compound mice are presented.
Journal ArticleDOI
Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation
Yotaro Kudo,Keisuke Tateishi,Keisuke Yamamoto,Shinzo Yamamoto,Yoshinari Asaoka,Hideaki Ijichi,Genta Nagae,Haruhiko Yoshida,Hiroyuki Aburatani,Kazuhiko Koike +9 more
TL;DR: The findings suggest that the amount of 5‐hmC in tumors is often reduced via various mechanisms, including the downregulation of TET1, and the critical roles of aberrant DNA demethylation for oncogenic processes in solid tissues are suggested.
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Journal ArticleDOI
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Hideaki Ijichi,Anna Chytil,Agnieszka E. Gorska,Mary Aakre,Brian Bierie,Motohisa Tada,Dai Mohri,Koji Miyabayashi,Yoshinari Asaoka,Shin Maeda,Tsuneo Ikenoue,Keisuke Tateishi,Christopher V.E. Wright,Kazuhiko Koike,Masao Omata,Harold L. Moses +15 more
TL;DR: The data indicate that tumor-stromal interactions via a Cxcr2-dependent chemokine and Ctgf axis can regulate PDAC progression and suggest that inhibiting tumor-stromal interactions might be a promising therapeutic strategy for PDAC.
Journal ArticleDOI
Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner
Bayasi Guleng,Keisuke Tateishi,Miki Ohta,Fumihiko Kanai,Amarsanaa Jazag,Hideaki Ijichi,Yasuo Tanaka,Miwa Washida,Keita Morikane,Yasushi Fukushima,Takao Yamori,Takashi Tsuruo,Takao Kawabe,Makoto Miyagishi,Kazunari Taira,Masataka Sata,Masao Omata +16 more
TL;DR: The data indicate that the SDF-1/CXCR4 pathway might be a general target for anticancer strategies and that blocking this system could be cooperatively effective in combination with other antiangiogenic therapies, such as blockade of VEGF.